These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178 [TBL] [Abstract][Full Text] [Related]
27. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995 [TBL] [Abstract][Full Text] [Related]
28. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086 [TBL] [Abstract][Full Text] [Related]
29. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786 [TBL] [Abstract][Full Text] [Related]
30. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951 [TBL] [Abstract][Full Text] [Related]
31. Improved outcomes of allogeneic hematopoietic stem cell transplantation including haploidentical transplantation for childhood myelodysplastic syndrome. Yoo JW; Im HJ; Kim H; Koh KN; Kang SH; Min SY; Choi ES; Jang S; Park CJ; Seo JJ Bone Marrow Transplant; 2020 Aug; 55(8):1595-1603. PubMed ID: 32054998 [TBL] [Abstract][Full Text] [Related]
32. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Clavio M; Crisà E; Miglino M; Guolo F; Ceccarelli M; Salvi F; Allione B; Ferrero D; Balleari E; Finelli C; Poloni A; Selleri C; Danise P; Cilloni D; Di Tucci AA; Cametti G; Freilone R; Fanin R; Bigazzi C; Zambello R; Crugnola M; Oliva EN; Centurioni R; Alesiani F; Catarini M; Castelli A; Abbadessa A; Capalbo SF; Musto P; Angelucci E; Santini V Cancer; 2021 Jun; 127(12):2015-2024. PubMed ID: 33739457 [TBL] [Abstract][Full Text] [Related]
33. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443 [TBL] [Abstract][Full Text] [Related]
34. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166 [TBL] [Abstract][Full Text] [Related]
35. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. Nakamura R; Saber W; Martens MJ; Ramirez A; Scott B; Oran B; Leifer E; Tamari R; Mishra A; Maziarz RT; McGuirk J; Westervelt P; Vasu S; Patnaik M; Kamble R; Forman SJ; Sekeres MA; Appelbaum F; Mendizabal A; Logan B; Horowitz M; Cutler C J Clin Oncol; 2021 Oct; 39(30):3328-3339. PubMed ID: 34106753 [TBL] [Abstract][Full Text] [Related]
36. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
37. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. Jentzsch M; Döhring C; Linke R; Hille A; Grimm J; Pönisch W; Vucinic V; Franke GN; Behre G; Niederwieser D; Schwind S Am J Hematol; 2019 Dec; 94(12):1344-1352. PubMed ID: 31495933 [TBL] [Abstract][Full Text] [Related]